Lasmiditan
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 221 publications
A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US.
Journal: Cephalalgia : an international journal of headache
Published: June 11, 2026
Real-World Safety and Effectiveness of Lasmiditan in Patients with Migraine: A Post-Marketing Observational Study in Japan.
Journal: Neurology and therapy
Published: February 25, 2026
From structural evolution to an AI-driven future of 5-HT1F receptor agonists for migraine therapy.
Journal: European journal of medicinal chemistry
Published: January 26, 2026
Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: January 09, 2026
The implications of losing treatment options: Why lasmiditan's discontinuation matters.
Journal: Headache
Published: November 25, 2025
5-Hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice.
Journal: American journal of physiology. Renal physiology
Published: October 08, 2025
Lasmiditan in Migraine Management: An Advanced Review of Its Pharmacological Paradigm, Clinical Applications, Safety Considerations, Drug Interaction Spectrum, and Regulatory Approval.
Journal: Drug research
Published: September 24, 2025
Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study).
Journal: Therapeutic advances in neurological disorders
Published: June 25, 2025
Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice.
Journal: Experimental neurology
Published: June 15, 2025
Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription.
Journal: Therapeutic advances in neurological disorders
Published: June 03, 2025
The Spectrum of Headaches in Moyamoya Angiopathy: From Mechanisms to Management Strategies-A Consensus Review From the NEUROVASC Working Group.
Journal: European journal of neurology
Published: May 31, 2025
Integrative snRNA-seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease.
Journal: Clinical and translational medicine
Published: May 26, 2025
Last Updated: 06/30/2026